{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:12:26Z","timestamp":1789589546426,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200717"],"award-info":[{"award-number":["32200717"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202504"],"award-info":[{"award-number":["82202504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["20210302123078"],"award-info":[{"award-number":["20210302123078"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.amjms.2023.11.016","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T01:30:41Z","timestamp":1700357441000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Construction of a hepatocellular carcinoma high-risk population rating scale and independent predictors' assessment"],"prefix":"10.1016","volume":"367","author":[{"given":"Manyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10127","key":"10.1016\/j.amjms.2023.11.016_bib0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.amjms.2023.11.016_bib0002","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.amjms.2023.11.016_bib0003","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ijc.33313","article-title":"Is it possible to halve the incidence of liver cancer in China by 2050?","volume":"148","author":"Shi","year":"2021","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.amjms.2023.11.016_bib0004","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.amjms.2023.11.016_bib0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.amjms.2023.11.016_bib0006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0007","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0008","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.amjms.2023.11.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103596","article-title":"The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study","volume":"170","author":"Santoni","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2022.2009455","article-title":"Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials","volume":"31","author":"Di Federico","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17474124.2022.2064273","article-title":"Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?","volume":"16","author":"Rizzo","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"22","key":"10.1016\/j.amjms.2023.11.016_bib0012","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.3748\/wjg.v21.i22.6999","article-title":"Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma","volume":"21","author":"Ilikhan","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"37","key":"10.1016\/j.amjms.2023.11.016_bib0013","doi-asserted-by":"crossref","first-page":"10573","DOI":"10.3748\/wjg.v21.i37.10573","article-title":"Biomarkers for the early diagnosis of hepatocellular carcinoma","volume":"21","author":"Tsuchiya","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjms.2023.11.016_bib0014","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejrad.2018.01.025","article-title":"Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines","volume":"101","author":"Ayuso","year":"2018","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.amjms.2023.11.016_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis"},{"issue":"2","key":"10.1016\/j.amjms.2023.11.016_bib0016","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12253-019-00585-5","article-title":"Current Status and Perspective Biomarkers in AFP Negative HCC: towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage","volume":"26","author":"Luo","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.amjms.2023.11.016_bib0017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev.med.080608.100623","article-title":"Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy","volume":"61","author":"Villanueva","year":"2010","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.amjms.2023.11.016_bib0018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0019","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjms.2023.11.016_bib0020","first-page":"1","article-title":"Report of a WHO expert committee","volume":"854","year":"1995","journal-title":"World Health Organ Tech Rep Ser."},{"key":"10.1016\/j.amjms.2023.11.016_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118058","article-title":"The pre-lumbar puncture intracranial hypertension scale (PLIHS): a practical scale to identify subjects with normal cerebrospinal fluid pressure in the management of idiopathic intracranial hypertension","volume":"429","author":"Raggi","year":"2021","journal-title":"J Neurol Sci"},{"issue":"18","key":"10.1016\/j.amjms.2023.11.016_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810423","article-title":"Inflammatory biomarkers associated with in-hospital mortality in critical COVID-19 patients","volume":"23","author":"P\u00e1l","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.amjms.2023.11.016_bib0023","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.amjms.2023.11.016_bib0024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic Hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2188\/jea.JE20100190","article-title":"Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures","volume":"21","author":"Tanaka","year":"2011","journal-title":"J Epidemiol"},{"issue":"1","key":"10.1016\/j.amjms.2023.11.016_bib0026","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3892\/etm.2011.351","article-title":"Smoking and hepatocellular carcinoma mortality","volume":"3","author":"Siegel","year":"2012","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0027","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3350\/cmh.2020.0203","article-title":"Alcohol and hepatocarcinogenesis","volume":"26","author":"Taniai","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.amjms.2023.11.016_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00042737-200101000-00009","article-title":"Oxidative damage in alcoholic liver disease","volume":"13","author":"Hagym\u00e1si","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.amjms.2023.11.016_bib0029","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease","volume":"70","author":"Ganne-Carri\u00e9","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.amjms.2023.11.016_bib0030","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2002.36780","article-title":"Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus","volume":"36","author":"Hassan","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0031","first-page":"369","article-title":"Eight-year follow-up of the 90,000-person Haimen City cohort: I. hepatocellular carcinoma mortality, risk factors, and gender differences","volume":"11","author":"Evans","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"10.1016\/j.amjms.2023.11.016_bib0032","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3748\/wjg.v11.i23.3491","article-title":"Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients","volume":"11","author":"Wong","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0033","first-page":"356","article-title":"Is higher bmi associated with worse overall mortality in hepatocellular carcinoma patients? An evidence based case report","volume":"51","author":"Fahira","year":"2019","journal-title":"Acta Med Indones"},{"issue":"17","key":"10.1016\/j.amjms.2023.11.016_bib0034","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjms.2023.11.016_bib0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00423-017-1589-2","article-title":"Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas","volume":"402","author":"Hashimoto","year":"2017","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.amjms.2023.11.016_bib0036","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12957-015-0713-4","article-title":"Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma","volume":"13","author":"Li","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"9","key":"10.1016\/j.amjms.2023.11.016_bib0037","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/ajg.2009.248","article-title":"Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels","volume":"104","author":"Nguyen","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjms.2023.11.016_bib0038","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0039","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s12072-021-10263-x","article-title":"Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines","volume":"15","author":"Teng","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.amjms.2023.11.016_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","article-title":"Creatinine: from physiology to clinical application","volume":"72","author":"Kashani","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.amjms.2023.11.016_bib0041","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajcn\/37.3.478","article-title":"Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method","volume":"37","author":"Heymsfield","year":"1983","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.amjms.2023.11.016_bib0042","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.amjmed.2016.11.020","article-title":"Prognostic Importance of Low Admission Serum Creatinine Concentration for Mortality in Hospitalized Patients","volume":"130","author":"Thongprayoon","year":"2017","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.amjms.2023.11.016_bib0043","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/hepr.13230","article-title":"Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma","volume":"49","author":"Tamai","year":"2019","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.amjms.2023.11.016_bib0044","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/1878-0261.12639","article-title":"Metabolism-associated molecular classification of hepatocellular carcinoma","volume":"14","author":"Yang","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.amjms.2023.11.016_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-511X-5-4","article-title":"Influence of liver cancer on lipid and lipoprotein metabolism","volume":"5","author":"Jiang","year":"2006","journal-title":"Lipids Health Dis"},{"issue":"11 Suppl 2","key":"10.1016\/j.amjms.2023.11.016_bib0046","article-title":"The influence of metabolic syndrome in the outcomes of colorectal cancer patients","author":"Goulart","year":"2017","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0047","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/cam4.695","article-title":"Blood lipids and prostate cancer: a Mendelian randomization analysis","volume":"5","author":"Bull","year":"2016","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0048","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/ijc.30818","article-title":"The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort","volume":"141","author":"Nderitu","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.amjms.2023.11.016_bib0049","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.amjms.2023.11.016_bib0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","article-title":"Versatile functions for IL-6 in metabolism and cancer","volume":"36","author":"Mauer","year":"2015","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.amjms.2023.11.016_bib0051","first-page":"622","article-title":"Blood sugar level affects the recurrence of hepatocellular carcinoma after laparoscopic surgery: a retrospective study","volume":"23","author":"Yu","year":"2018","journal-title":"J buon"},{"issue":"6","key":"10.1016\/j.amjms.2023.11.016_bib0052","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"Kramer","year":"2022","journal-title":"Hepatology"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962923014167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962923014167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:16:30Z","timestamp":1762082190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962923014167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0002962923014167"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2023.11.016","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction of a hepatocellular carcinoma high-risk population rating scale and independent predictors' assessment","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2023.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}